(Q37336356)

19 August 2017

Phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with recurrent or metastatic gastric cancer (English)

1 reference

19 August 2017

1 reference

1 reference

1 reference

Kyung-Ha Kim

1

1 reference

19 August 2017

Ki-Ju Jeung

2

1 reference

19 August 2017

Hyun-Jung Kim

3

1 reference

19 August 2017

Sang-Byung Bae

4

1 reference

19 August 2017

Chan-Kyu Kim

5

1 reference

19 August 2017

Nam-Su Lee

6

1 reference

19 August 2017

Kyu-Taek Lee

7

1 reference

19 August 2017

Sung-Kyu Park

8

1 reference

19 August 2017

Jong-Ho Won

9

1 reference

19 August 2017

Dae-Sik Hong

10

1 reference

19 August 2017

Hee-Sook Park

11

1 reference

19 August 2017

language of work or name

1 reference

30 June 2007

1 reference

Cancer Research and Treatment

19 August 2017

1 reference

19 August 2017

39

1 reference

19 August 2017

2

1 reference

19 August 2017

49-53

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

19 August 2017

start time

30 June 2007

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739318

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739318

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739318

Reporting results of cancer treatment

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739318

Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739318

Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739318

Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: a multicenter phase I/II study

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739318

Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739318

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739318

Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19746213

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4143/CRT.2007.39.2.49

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

19746213

1 reference